In a highly anticipated head-to-head trial of Eli Lilly’s Zepbound (tirzepatide) and Novo Nordisk’s Wegovy (semaglutide), Zepbound has come out on top as it helped trial participants lose significantly more weight than Wegovy over an 18-month period. Patients treated with Zepbound achieved an average weight loss of 20.2 percent of their body weight, compared to […]
